BioLife Solutions (BLFS) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 01, 2019
Document Information [Line Items]
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Entity Central Index Key	0000834365
Trading Symbol	blfs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		18,799,386
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Balance Sheets (Current Period

Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 31,824,000	$ 30,657,000
Accounts receivable, trade, net of allowance for doubtful accounts of $0 at March 31, 2019 and December 31, 2018	2,927,000	3,045,000
Inventories	4,060,000	3,509,000
Prepaid expenses and other current assets	346,000	353,000
Total current assets	39,157,000	37,564,000
Property and equipment
Leasehold improvements	1,284,000	1,284,000
Furniture and computer equipment	704,000	706,000
Manufacturing and other equipment	1,803,000	1,657,000
Subtotal	3,791,000	3,647,000
Less: Accumulated depreciation	(2,424,000)	(2,328,000)
Net property and equipment	1,367,000	1,319,000
Operating lease right-of-use assets	1,196,000
Investment in SAVSU	6,317,000	6,548,000
Long-term deposits	36,000	36,000
Total assets	48,073,000	45,467,000
Current liabilities
Accounts payable	1,264,000	720,000
Accrued expenses and other current liabilities	142,000	91,000
Accrued compensation	630,000	998,000
Lease liability - operating, current portion	651,000
Lease liability – financing, current portion	14,000
Deferred rent, current portion		130,000
Total current liabilities	2,701,000	1,939,000
Deferred rent, long-term		349,000
Long-term lease liability - operating	980,000
Long-term lease liability - financing	13,000
Other long-term liabilities	13,000	31,000
Total liabilities	3,707,000	2,319,000
Commitments and Contingencies (Note 8)
Shareholders’ equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 18,717,095 and 18,547,406 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	19,000	19,000
Additional paid-in capital	114,951,000	114,160,000
Accumulated deficit	(70,604,000)	(71,031,000)
Total shareholders’ equity	44,366,000	43,148,000
Total liabilities and shareholders’ equity	$ 48,073,000	$ 45,467,000

Balance Sheets (Current Perio_2

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 0	$ 0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	18,717,095	18,547,406
Common stock, outstanding (in shares)	18,717,095	18,547,406

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Product revenue	$ 5,770,000	$ 3,815,000
Cost of product sales	1,647,000	1,364,000
Gross profit	4,123,000	2,451,000
Operating expenses
Research and development	372,000	346,000
Sales and marketing	848,000	612,000
General and administrative	2,204,000	1,353,000
Acquisition costs	208,000
Total operating expenses	3,632,000	2,311,000
Operating income	491,000	140,000
Other income (expense), net
Interest income	171,000	8,000
Interest expense	(3,000)	(1,000)
Loss from equity-method investment in SAVSU	(232,000)	(144,000)
Total other income (expenses), net	(64,000)	(137,000)
Net income	427,000	3,000
Less: Preferred stock dividends		(106,000)
Net income (loss) attributable to common stockholders	$ 427,000	$ (103,000)
Basic net income (loss) per common share (in dollars per share)	$ 0.02	$ (0.01)
Diluted net income (loss) per common share (in dollars per share)	$ 0.02	$ (0.01)
Weighted average shares outstanding used to compute basic earnings per share (in shares)	18,648,397	14,098,610
Weighted average shares outstanding used to compute diluted earnings per share (in shares)	24,358,475	14,098,610

Statements of Shareholders' Equ

Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	4,250	14,021,422
Balance at Dec. 31, 2017		$ 14	$ 84,036	$ (73,958)	$ 10,092
Stock based compensation			373		373
Stock option/warrant exercises (in shares)		62,438
Stock option/warrant exercises			73		73
Stock issued – on vested RSUs (in shares)		55,614
Stock issued – on vested RSUs
Stock issued for services (in shares)		5,939
Stock issued for services			36		36
Preferred stock dividends				(106)	(106)
Net income				3	3
Balance (in shares) at Mar. 31, 2018	4,250	14,145,413
Balance at Mar. 31, 2018		$ 14	84,518	(74,061)	10,471
Balance (in shares) at Dec. 31, 2018		18,547,406
Balance at Dec. 31, 2018		$ 19	114,160	(71,031)	43,148
Stock based compensation			606		606
Stock option/warrant exercises (in shares)		104,697
Stock option/warrant exercises			185		185
Stock issued – on vested RSUs (in shares)		64,992
Stock issued – on vested RSUs
Net income				427	427
Balance (in shares) at Mar. 31, 2019		18,717,095
Balance at Mar. 31, 2019		$ 19	$ 114,951	$ (70,604)	$ 44,366

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net income	$ 427,000	$ 3,000
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	98,000	78,000
Stock-based compensation expense	606,000	373,000
Amortization of operating lease liability	(43,000)
Interest expense – finance type lease	2,000
Amortization of deferred rent related to lease incentives	0	(32,000)
Loss from equity-method investment in SAVSU	232,000	144,000
Change in operating assets and liabilities
Accounts receivable, trade	118,000	(23,000)
Inventories	(551,000)	10,000
Prepaid expenses and other current assets	6,000	12,000
Accounts payable	553,000	(69,000)
Accrued compensation and other current liabilities	(302,000)	(101,000)
Deferred rent		(3,000)
Net cash provided by operating activities	1,146,000	392,000
Cash flows from investing activities
Purchase of property and equipment	(156,000)	(41,000)
Net cash used in investing activities	(156,000)	(41,000)
Cash flows from financing activities
Payments on equipment loan	(4,000)	(3,000)
Payments on capital lease obligation/finance lease	(4,000)	(3,000)
Proceeds from exercise of common stock options and warrants	185,000	73,000
Cash received in advance of issuance of stock on warrant exercises		57,000
Payments of preferred stock dividends		(106,000)
Net cash provided by financing activities	177,000	18,000
Net increase in cash and cash equivalents	1,167,000	369,000
Cash and cash equivalents - beginning of period	30,657,000	6,663,000
Cash and cash equivalents - end of period	31,824,000	7,032,000
Non-cash investing and financing activities
Stock issued for services provided in prior period included in liabilities at year-end		36,000
Purchase of equipment with debt		18,000
Series A preferred stock dividends accrued not yet paid		106,000
Purchase of property & equipment not yet paid	$ 46,000

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) a leading developer, manufacturer and supplier of proprietary biopreservation media and automated thawing devices for cells and gene therapies. Our CryoStor ® ® 11 Basis of Presentation We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2018 There have been no 10 December 31, 2018. Significant Accounting Policies Update In February 2016, No. 2016 02, 842 2016 02” 2016 02. We adopted ASU 2016 02 842 January 1, 2019 not January 1, 2019 840, January 1, 2019. The adoption of this standard resulted in the recording of operating lease right-of-use assets of $1.3 $1.8 January 1, 2019. $0.5 842. 842 not no Equity Method Investments We account for our ownership in SAVSU Technologies, Inc. (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, 44.4% March 31, 2019 December 31, 2018. three March 31, 2019 2018, $522,000 $538,000, Concentrations of credit risk and business risk In the three March 31, 2019, 34% two three March 31, 2018, 30% two No 10% three March 31, 2019 2018. three March 31, 2019 2018, 90% 86%, March 31, 2019, two 45% December 31, 2018, three 71% Revenue from customers located in Canada represented 23% 17% three March 31, 2019. 12% 13% three March 31, 2018. Recent Accounting Pronouncements There have been no not

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair Value Measurement In accordance with FASB Accounting Standards Codification (“ASC”) Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 As of March 31, 2019 December 31, 2018, not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2019 December 31, 2018, three (I n thousands) As of March 31, 2019 Level 1 Level 2 Total Total cash and cash equivalents $ 31,824 $ — $ 31,824 As of December 31, 2018 Level 1 Level 2 Total Total cash and cash equivalents $ 30,657 $ — $ 30,657 The fair values of cash and cash equivalents classified as Level 1 no 2 3 not 1 2 three March 31, 2019 twelve December 31, 2018.

Note 3 - Inventory

Note 3 - Inventory	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventory consists of the following at March 31, 2019 December 31, 2018: (I n thousands) March 31, 2019 December 31, 2018 Raw materials $ 1,629 $ 1,453 Work in progress 949 652 Finished goods 1,482 1,404 Total $ 4,060 $ 3,509

Note 4 - Deferred Rent

Note 4 - Deferred Rent	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Deferred Rent [Text Block]	4. Deferred Rent Deferred rent consists of the following at December 31, 2018. January 1, 2019 2016 02 10 (I n thousands) December 31, 2018 Landlord-funded leasehold improvements $ 1,125 Less accumulated amortization (757 ) Total 368 Straight line rent adjustment 111 Total deferred rent $ 479 During the three March 31, 2019 2018, none $32,000, Straight line rent adjustment for the three March 31, 2018

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	5. Share-based Compensation Service Vesting-Based Stock Options The following is a summary of service vesting based stock option activity for the three March 31, 2019, March 31, 2019: Three Month Period Ended March 31, 2019 Weighted Avg. Exercise Options Price Outstanding at beginning of year 2,043,402 $ 1.91 Granted — $ N/A Exercised (99,697 ) $ 1.61 Forfeited (3,438 ) $ 5.69 Expired — $ N/A Outstanding at March 31, 2019 1,940,267 $ 1.92 Stock options exercisable at March 31, 2019 1,657,436 $ 1.89 We recognized stock compensation expense of $144,000 $153,000 three March 31, 2019 2018, March 31, 2019, $31.0 $26.5 March 31, 2019. March 31, 2019 2018 $1.4 $270,000, March 31, 2019 5.4 5.3 March 31, 2019 $374,000 1.4 Performance-based Stock Options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 1,000,000 may $1.64, 2017 50% 2017, 50% one not no February 27, 2018, 2017 999,997 50% March 8, 2018 50% March 8, 2019. We recognized stock compensation expense of none $125,000 three March 31, 2019 2018, March 31, 2019, $15.7 March 31, 2019. March 31, 2019 2018 no March 31, 2019, 2.7 no March 31, 2019. 964,997 three March 31, 2019. There were no three March 31, 2019 2018. Restricted Stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the three March 31, 2019, March 31, 2019: Three Month Period Ended March 31, 2019 Number of Grant-Date Unvested outstanding at beginning of year 279,919 $ 5.00 Granted 146,614 $ 17.84 Vested (64,992 ) $ 4.47 Forfeited (8,418 ) $ 6.66 Unvested outstanding at March 31, 2019 353,123 $ 10.39 The aggregate fair value of the service vesting-based awards granted during the three March 31, 2019 2018 $2.6 $1.0 $853,000 $307,000 three March 31, 2019 March 31, 2018, We recognized stock compensation expense of $255,000 $95,000 three March 31, 2019 March 31, 2018, March 31, 2019, $3.5 3.6 Performance -based restricted stock In 2019, 94,247 four 94,247 0% 200% January 1, 2019 December 31, 2020 20 94,247 50th may 188,494 80th no 30th During the three March 31, 2019, 94,247 $17.84. $1.7 $207,000 three March 31, 2019. March 31, 2019, $1.5 1.8 We recorded total stock compensation expense for the three March 31, 2019 2018, Three Month Period Ended March 31, (I n thousands) 2019 2018 Research and development costs $ 80 $ 65 Sales and marketing costs 166 69 General and administrative costs 328 191 Cost of product sales 32 48 Total $ 606 $ 373

Note 6 - Warrants

Note 6 - Warrants	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Warrants [Text Block]	6. At March 31, 2019 December 31, 2018, 4,075,005 4,080,005 $4.35 three March 31, 2019, 5,000 $4.75, $24,000

Note 7 - Net Loss Per Common Sh

Note 7 - Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	7. Basic earnings per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the three March 31, 2019, three March 31, 2018, 3.3 6.7 338,000 The following table shows the calculation of basic and diluted earnings per shares: Three Month Period Ended March 31, (In thousands, except per share and share data) 2019 2018 Numerator: Net income (loss) attributable to common stockholders $ 427 $ (103 ) Denominator: Weighted average basic shares outstanding 18,648,397 14,098,610 Effect of dilutive securities 5,710,078 — Weighted average diluted shares 24,358,475 14,098,610 Basic earnings per share $ 0.02 $ (0.01 ) Diluted earnings per share $ 0.02 $ (0.01 )

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Employment agreements We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, and Vice President of Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none

Note 9 - Revenue

Note 9 - Revenue	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	9 . Revenue We currently operate as one The following table disaggregates revenue by market segment and distributors: Three Months Ended March 31, (I n thousands) 2019 2018 Net product sales: Regenerative medicine $ 2,179 $ 2,104 Drug discovery 238 377 BioBanking 249 295 Distributors 3,104 1,039 Total revenues $ 5,770 $ 3,815

Note 10 - Leases

Note 10 - Leases	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Lessee, Leases [Text Block]	10. Our operating leases are primarily related to our Bothell, Washington headquarters space lease. The term of our lease continues until July 31, 2021 two five first August 1, 2021, second first not not 6.5%, 8.1%, 2.3 1.9 three March 31, 2019 $142,000 $186,000, Maturities of lease liabilities as of March 31, 2019 (In thousands) Operating Leases Financing Leases 2019 (less than one year) $ 548 $ 11 2020 764 15 2021 451 3 Total lease payments 1,763 29 Less: interest (132 ) (2 ) Total present value of lease liabilities $ 1,631 $ 27

Note 11 - Subsequent Event

Note 11 - Subsequent Event	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 1 . Subsequent Event On April 1, 2019, 100% $8 $4.5 $8.0 three We incurred $208,000 three March 31, 2019, April 1, 2019. Due to the limited time since the acquisition date and the effort required to assess the fair value of assets acquired and liabilities assumed, the initial accounting for the business combination is incomplete at the time of this filing. As a result, the Company is unable to provide the amounts recognized for the major classes of assets acquired and liabilities assumed, acquisition contingencies and goodwill. Also, the Company is unable to provide pro forma revenues and earnings of the combined entity. This information is expected to be included in the Company's Quarterly Report on Form 10 June 30, 2019.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2018 There have been no 10 December 31, 2018. Significant Accounting Policies Update In February 2016, No. 2016 02, 842 2016 02” 2016 02. We adopted ASU 2016 02 842 January 1, 2019 not January 1, 2019 840, January 1, 2019. The adoption of this standard resulted in the recording of operating lease right-of-use assets of $1.3 $1.8 January 1, 2019. $0.5 842. 842 not no
Equity Method Investments [Policy Text Block]	Equity Method Investments We account for our ownership in SAVSU Technologies, Inc. (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, 44.4% March 31, 2019 December 31, 2018. three March 31, 2019 2018, $522,000 $538,000,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk In the three March 31, 2019, 34% two three March 31, 2018, 30% two No 10% three March 31, 2019 2018. three March 31, 2019 2018, 90% 86%, March 31, 2019, two 45% December 31, 2018, three 71% Revenue from customers located in Canada represented 23% 17% three March 31, 2019. 12% 13% three March 31, 2018.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There have been no not

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of March 31, 2019 Level 1 Level 2 Total Total cash and cash equivalents $ 31,824 $ — $ 31,824 As of December 31, 2018 Level 1 Level 2 Total Total cash and cash equivalents $ 30,657 $ — $ 30,657

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(I n thousands) March 31, 2019 December 31, 2018 Raw materials $ 1,629 $ 1,453 Work in progress 949 652 Finished goods 1,482 1,404 Total $ 4,060 $ 3,509

Note 4 - Deferred Rent (Tables)

Note 4 - Deferred Rent (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Deferred Rent [Table Text Block]	(I n thousands) December 31, 2018 Landlord-funded leasehold improvements $ 1,125 Less accumulated amortization (757 ) Total 368 Straight line rent adjustment 111 Total deferred rent $ 479

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Three Month Period Ended March 31, 2019 Weighted Avg. Exercise Options Price Outstanding at beginning of year 2,043,402 $ 1.91 Granted — $ N/A Exercised (99,697 ) $ 1.61 Forfeited (3,438 ) $ 5.69 Expired — $ N/A Outstanding at March 31, 2019 1,940,267 $ 1.92 Stock options exercisable at March 31, 2019 1,657,436 $ 1.89
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Three Month Period Ended March 31, 2019 Number of Grant-Date Unvested outstanding at beginning of year 279,919 $ 5.00 Granted 146,614 $ 17.84 Vested (64,992 ) $ 4.47 Forfeited (8,418 ) $ 6.66 Unvested outstanding at March 31, 2019 353,123 $ 10.39
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Month Period Ended March 31, (I n thousands) 2019 2018 Research and development costs $ 80 $ 65 Sales and marketing costs 166 69 General and administrative costs 328 191 Cost of product sales 32 48 Total $ 606 $ 373

Note 7 - Net Loss Per Common _2

Note 7 - Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Month Period Ended March 31, (In thousands, except per share and share data) 2019 2018 Numerator: Net income (loss) attributable to common stockholders $ 427 $ (103 ) Denominator: Weighted average basic shares outstanding 18,648,397 14,098,610 Effect of dilutive securities 5,710,078 — Weighted average diluted shares 24,358,475 14,098,610 Basic earnings per share $ 0.02 $ (0.01 ) Diluted earnings per share $ 0.02 $ (0.01 )

Note 9 - Revenue (Tables)

Note 9 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, (I n thousands) 2019 2018 Net product sales: Regenerative medicine $ 2,179 $ 2,104 Drug discovery 238 377 BioBanking 249 295 Distributors 3,104 1,039 Total revenues $ 5,770 $ 3,815

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2019 (less than one year) $ 548 $ 11 2020 764 15 2021 451 3 Total lease payments 1,763 29 Less: interest (132 ) (2 ) Total present value of lease liabilities $ 1,631 $ 27

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Operating Lease, Right-of-Use Asset	$ 1,196,000			$ 1,300,000
Operating Lease, Liability, Total	1,631,000			1,800,000
Net Income (Loss) Attributable to Parent, Total	$ 427,000	$ 3,000
Deferred Rent Credit			$ 479,000
Accounting Standards Update 2016-02 [Member]
Deferred Rent Credit				$ 500,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	34.00%	30.00%
Number of Major Customers	2	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CANADA
Concentration Risk, Percentage	23.00%	12.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]
Concentration Risk, Percentage	17.00%	13.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CryoStor Products [Member]
Concentration Risk, Percentage	90.00%	86.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	45.00%		71.00%
Number of Major Customers	2		3
SAVSU [Member]
Net Income (Loss) Attributable to Parent, Total	$ 522,000	$ 538,000
SAVSU [Member]
Equity Method Investment, Ownership Percentage	44.40%		44.40%

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	$ 0	$ 0

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents	$ 0	$ 0
Fair Value, Recurring [Member]
Total cash and cash equivalents	31,824	30,657
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total cash and cash equivalents	31,824	30,657
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents

Note 3 - Inventory - Summary of

Note 3 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Raw materials	$ 1,629	$ 1,453
Work in progress	949	652
Finished goods	1,482	1,404
Total	$ 4,060	$ 3,509

Note 4 - Deferred Rent (Details

Note 4 - Deferred Rent (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Amortization of Deferred Rent	$ 0	$ 32,000

Note 4 - Deferred Rent - Summar

Note 4 - Deferred Rent - Summary of Deferred Rent (Details) $ in Thousands	Dec. 31, 2018USD ($)
Landlord-funded leasehold improvements	$ 1,125
Less accumulated amortization	(757)
Total	368
Straight line rent adjustment	111
Total deferred rent	$ 479

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Feb. 27, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Share-based Payment Arrangement, Expense		$ 606,000	$ 373,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		144,000	153,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		31,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		26,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 1,400,000	$ 270,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		5 years 146 days	5 years 109 days
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 374,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 146 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		99,697
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,940,267			2,043,402
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Share-based Payment Arrangement, Expense		$ 0	$ 125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		15,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 15,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		2 years 255 days
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price				$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	999,997
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		964,997
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		0	0
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting on Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting One Year After Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Restricted Stock [Member]
Share-based Payment Arrangement, Expense		$ 255,000	$ 95,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 3,500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		3 years 219 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value		$ 2,600,000	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 853,000	$ 307,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance		353,123			279,919
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance		$ 10.39			$ 5
Performance-based Restricted Stock [Member]
Share-based Payment Arrangement, Expense		$ 207,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 1,500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		94,247
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance		94,247
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance		$ 17.84
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding		$ 1,700,000
Performance-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards		0.00%
Performance-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		188,494
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards		200.00%

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Option Activity (Details) - Share-based Payment Arrangement, Option [Member]	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Outstanding (in shares)	2,043,402
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ / shares	$ 1.91
Granted (in shares)
Exercised (in shares)	(99,697)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 1.61
Forfeited (in shares)	(3,438)
Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 5.69
Expired (in shares)
Expired, weighted average exercise price (in dollars per share) | $ / shares
Outstanding (in shares)	1,940,267
Outstanding at end of year, weighted average exercise price (in dollars per share) | $ / shares	$ 1.92
Stock options exercisable (in shares)	1,657,436
Stock options exercisable at year end, weighted average exercise price (in dollars per share) | $ / shares	$ 1.89

Note 5 - Share-based Compensa_5

Note 5 - Share-based Compensation - Restricted Stock Activity (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Unvested outstanding (in shares) | shares	279,919
Unvested outstanding, grant date fair value (in dollars per share) | $ / shares	$ 5
Unvested granted (in shares) | shares	146,614
Granted, grant date fair value (in dollars per share) | $ / shares	$ 17.84
Vested (in shares) | shares	(64,992)
Vested, grant date fair value (in dollars per share) | $ / shares	$ 4.47
Forfeited (in shares) | shares	(8,418)
Forfeited, grant date fair value (in dollars per share) | $ / shares	$ 6.66
Unvested outstanding (in shares) | shares	353,123
Unvested outstanding, grant date fair value (in dollars per share) | $ / shares	$ 10.39

Note 5 - Share-based Compensa_6

Note 5 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock compensation expense	$ 606	$ 373
Research and Development Expense [Member]
Stock compensation expense	80	65
Selling and Marketing Expense [Member]
Stock compensation expense	166	69
General and Administrative Expense [Member]
Stock compensation expense	328	191
Cost of Sales [Member]
Stock compensation expense	$ 32	$ 48

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Class of Warrant or Right, Outstanding	4,075,005	4,080,005
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.35	$ 4.35
Class of Warrant or Right, Exercised During Period	5,000
Class of Warrant or Right, Exercised During Period, Exercise Price	$ 4.75
Proceeds from Warrant Exercises	$ 24,000

Note 7 - Net Loss Per Common _3

Note 7 - Net Loss Per Common Share (Details Textual)	3 Months Ended
	Mar. 31, 2018shares
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,300,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,700,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	338,000

Note 7 - Net Loss Per Common _4

Note 7 - Net Loss Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net income (loss) attributable to common stockholders	$ 427	$ (103)
Weighted average shares outstanding used to compute basic earnings per share (in shares)	18,648,397	14,098,610
Effect of dilutive securities (in shares)	5,710,078
Weighted average diluted shares (in shares)	24,358,475	14,098,610
Basic net income (loss) per common share (in dollars per share)	$ 0.02	$ (0.01)
Diluted net income (loss) per common share (in dollars per share)	$ 0.02	$ (0.01)

Note 9 - Revenue (Details Textu

Note 9 - Revenue (Details Textual)	3 Months Ended
	Mar. 31, 2019
Number of Operating Segments	1

Note 9 - Revenue - Disaggregate

Note 9 - Revenue - Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net product sales	$ 5,770	$ 3,815
Regenerative Medicine [Member]
Net product sales	2,179	2,104
Drug Discovery [Member]
Net product sales	238	377
BioBanking [Member]
Net product sales	249	295
Distribution Service [Member]
Net product sales	$ 3,104	$ 1,039

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)
Operating Lease, Weighted Average Discount Rate, Percent	6.50%
Finance Lease, Weighted Average Discount Rate, Percent	8.10%
Operating Lease, Weighted Average Remaining Lease Term	2 years 109 days
Finance Lease, Weighted Average Remaining Lease Term	1 year 328 days
Operating Lease, Cost	$ 142,000
Operating Lease, Payments	$ 186,000
Bothell, Washington Headquarters [Member]
Lessee, Operating Lease, Renewal Term	5 years

Note 10 - Leases - Maturities o

Note 10 - Leases - Maturities of Lease Liabilities (Details) - USD ($)	Mar. 31, 2019	Jan. 01, 2019
2019, operating leases	$ 548,000
2019, financing leases	11,000
2020, operating leases	764,000
2020, financing leases	15,000
2021, operating leases	451,000
2021, financing leases	3,000
Total operating lease payments	1,763,000
Total financing lease payments	29,000
Less: operating lease interest	(132,000)
Less: financing lease interest	(2,000)
Total present value of operating lease liabilities	1,631,000	$ 1,800,000
Total present value of financing lease liabilities	$ 27,000

Note 11 - Subsequent Event (Det

Note 11 - Subsequent Event (Details Textual) - USD ($)	Apr. 01, 2019	Mar. 31, 2019	Mar. 31, 2018
Business Combination, Acquisition Related Costs		$ 208,000
Astero [Member] | Subsequent Event [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Payments to Acquire Businesses, Gross	$ 8,000,000
Astero [Member] | Subsequent Event [Member] | Product Development Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	4,500,000
Astero [Member] | Subsequent Event [Member] | Revenue Targets [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 8,000,000